How do lifestyle factors play a role in the response to CAR-T therapy?
Ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models.
Cellular Therapy
News
Leukemia
Acute Myeloid Leukemia
News
Olutasidenib plus azacitidine show ‘durable’ responses in relapsed or refractory IDH1-mutated AML
The combination of olutasidenib plus azacitidine produced “durable” responses in patients with relapsed or refractory mIDH1 acute myeloid leukemia (AML), according to a
Cellular Therapy
Lymphoma
News
Society Updates
Young Investigator Program
SOHO Young Investigator Spotlight: Meet Megan Melody, MD
In every phase of my career while I’ve been training, I have been lucky to be mentored by the major movers and shakers
Leukemia
Acute Myeloid Leukemia
News
Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML
Lintuzumab-Ac225 plus CLAG-M yielded “deep and meaningful responses” in patients with relapsed/refractory acute myeloid leukemia (AML), according the results of a phase 1
Roundtable Discussions
MDS Roundtable
What is the patient journey for those undergoing blood transfusions?
In this roundtable discussion on anemia management in MDS, the panel discusses the journey of a patient undergoing blood transfusions.
Past Roundtable Discussions
Roundtable Discussions
MPN Roundtable
Can anemia agents improve outcomes with ruxolitinib in MPN?
In this video clip, the panel discusses the RR6 model's ability to predict outcomes for patients treated with ruxolitinib, particularly identifying those who
News
Roundtable Discussions
MPN Roundtable
Are there MPN therapies that improve platelets?
In this video segment of the MPN roundtable, the panel addresses common misconceptions about pacritinib, clarifying that while it enables JAK inhibition in
News
Roundtable Discussions
MPN Roundtable
Should luspatercept be used to treat myelofibrosis?
A roundtable discussion on anemia management in myeloproliferative neoplasms, featuring moderator John Mascarenhas, MD, Mount Sinai; Andrew Kuykendall, MD, Moffitt Cancer Center; and
News
Roundtable Discussions
MPN Roundtable
To add or switch therapy in MPN anemia?
Anemia remains a major challenge in the treatment of myeloproliferative neoplasms, especially for patients receiving ruxolitinib. In this expert roundtable, featuring moderator John
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Roundtable Discussions
MDS Roundtable
What’s changing in how we treat transfusion dependence in anemia?
In this segment of the MDS roundtable on anemia in lower-risk MDS, the panel, led by Guillermo Garcia-Manero discuss transfusion dependence.